Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells

Area of Science:

• Biotechnology
• Molecular Biology
• Cancer Research

Background:

• Gene expression control is crucial for targeted cancer therapies.
• A dual system combining transcriptional regulation and DNA recombination offers enhanced control.
• The prostate-specific antigen (PSA) promoter is a validated target for prostate cancer therapies.

Purpose of the Study:

• To investigate a novel dual gene expression control system for targeted cancer therapy.
• To evaluate the efficacy of a PSA promoter-driven Flp recombinase system regulating diphtheria toxin (DT-A) expression.
• To assess the therapeutic potential of this system in prostate cancer models.

Main Methods:

• Adenoviral delivery of DNA encoding PSA promoter-driven Flp recombinase and DT-A.
• Utilized human prostate cancer cells in culture, xenografts, and TRAMP mouse models.
• Monitored DT-A expression, tumor size reduction, and cell viability.

Main Results:

• DT-A expression was effectively activated in a manner correlating with PSA and androgen levels.
• Xenograft tumor size was reduced by 50% following treatment.
• Intratumoral injection of DT-A viruses led to significant tumor cell death and prostate size reduction in mice.

Conclusions:

• The PSA promoter-driven Flp recombinase system enables targeted death of PSA-expressing cells.
• This approach holds promise for developing effective systemically-administered therapies for metastatic prostate cancer.
• Further development combined with targeted gene delivery strategies could enhance therapeutic outcomes.